Cidara Therapeutics Q1 2024 GAAP EPS $(2.28) Misses $(0.20) Estimate, Sales $8.46M Beat $6.30M Estimate
Cidara Therapeutics Q1 2024 GAAP EPS $(2.28) Misses $(0.20) Estimate, Sales $8.46M Beat $6.30M Estimate
Cidara Therapeutics2024年第一季度GAAP每股收益美元（2.28美元）未達到預期（0.20美元），銷售額846萬美元超過630萬美元的預期
Cidara Therapeutics (NASDAQ:CDTX) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of $(0.20) by 1040 percent. The company reported quarterly sales of $8.46 million which beat the analyst consensus estimate of $6.30 million by 34.33 percent. This is a 67.44 percent decrease over sales of $25.99 million the same period last year.
cidara therapeutics (納斯達克：CDTX)報告每股虧損$(2.28)，比分析師共識估計的$(0.20)低1040%。該公司報告的季度銷售額爲$8.46百萬，比分析師共識估計的$6.30百萬高34.33%。這是與去年同期$25.99百萬的銷售額減少了67.44%。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。